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There is much debate around the preoperative treatment of colorectal cancer and, in particular, neoadjuvant
chemoradiotherapy in locally advanced rectal cancer. This treatment carries a significant risk of harmful side effects
and has a highly variable response rate. Predictive biomarkers have been the subject of a great deal of study with
the aim of pretreatment risk stratification in order to more accurately determine which patients will derive the most
benefit and least harm from these treatments. The study of epigenetics in colorectal cancer is relatively recent, and
distinct patterns of aberrant DNA methylation, in particular the cytosine-phosphate-guanine (CpG) island methylator
phenotype (CIMP), have been demonstrated in colorectal cancer, and their characterisation and significance are
under debate, particularly in rectal cancer. These patterns of DNA methylation have been associated with
differences in response to therapy and treatment outcomes and therefore have the potential to be used as
biomarkers in tailored therapy regimes for patients with rectal cancer. This review aims to summarise the current
state of the art in rectal cancer, with particular regard to the determination of DNA methylation patterns, the CpG
island methylator phenotype and its potential as a novel biomarker in rectal cancer treatment and prediction of
outcomes and response after neoadjuvant chemoradiotherapy.
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Neoadjuvant chemoradiotherapy is currently recom-
mended by the National Institute for Health and Clinical
Excellence (NICE) [1] prior to surgical resection for pa-
tients with advanced stage (T3–4) rectal tumours and
those with nodal disease in order to reduce rates of
locoregional recurrence and potential circumferential
margin involvement.
It is increasingly recognised that this preoperative
chemoradiotherapy is associated with significant adverse
effects including faecal and urinary incontinence, delayed
wound healing and sexual dysfunction [2]. Presently, there
are no biomarkers to predict the response of patients to
this treatment, which in itself is highly variable. Outcomes* Correspondence: dean.a.harris@wales.nhs.uk
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which occurs in 10–20 % [3] of patients, with up to 30 %
of patients who have no response to treatment [4].
If an accurate method to predict response to chemoradio-
therapy was available, then patients with radiation-resistant
disease would be spared the morbidity of this treatment,
and those with a prediction of pathological complete re-
sponse may ultimately be spared radical surgery.
Recently, attempts have been made to predict rectal
cancer patient’s response to chemoradiotherapy includ-
ing markers of cellular hypoxia [5], cellular expression of
proteins such as COX2 and CD133 [6] and various pro-
tein kinases [7]. The role of KRAS and BRAF mutations
has already been well established in their contribution to
resistance to anti-EGFR agents [8], but no role in
response to irradiation has been demonstrated [9, 10].
By contrast, studies of epigenetic silencing by aberrant
DNA methylation in a number of cancers, includingss article distributed under the terms of the Creative Commons Attribution
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oesophageal cancers [15], have revealed novel insights
into the response of tumours to radiotherapy with or
without chemotherapy. There have been similar efforts
in the study of DNA methylation in rectal cancers, and
this review aims to summarise the current state of the
art in this group of patients.
Review
DNA methylation and the CpG island methylator
phenotype (CIMP)
Aberrant DNA methylation of cytosine-phosphate-guan-
ine (CpG) islands has been reported widely in colorectal
tumours and is associated with gene silencing when it
occurs in promoter areas [16, 17]. CpG islands are typic-
ally short (300–3000 base pairs) cytosine-phosphodiester-
guanine-bonded sequences found in or around the
promoter region of a gene where they are usually
unmethylated if the genes are expressed.
Methylation affects gene expression directly by interfering
with transcription factor binding [18] and/or indirectly
by recruiting histone deacetylases through methyl-DNA-
binding proteins [19] to induce histone modification to-
wards a more compacted and repressive chromatin state. In
colorectal cancer cells, loss of DNA methylation has been
demonstrated to induce a conformational change at histone
H3K27 re-establishing its active transcriptional state resem-
bling that of a methylation-deficient cell line [20].
The CpG island methylator phenotype (CIMP) is
characterised by epigenetic DNA hypermethylation and
consequent suppression of key groups of genes that are
differentially methylated between normal and malig-
nant cells and are important in controlling cell growth
and survival.
DNA methylation is therefore necessary for the normal
growth and development of cells and can be detected
in normal as well as malignant colorectal mucosa [21].
In colorectal cancer, tumours with high-level CIMP-
associated methylation (CIMP high) are associated with a
particular subset of clinicopathological features including
a predilection for mucinous tumours of the proximal
colon and association with BRAF mutation [22]. CIMP-
high tumours are associated with between 2 and 10 % of
rectal cancers [23, 24]. However, some debate exists as to
the existence of an intermediate group with a low level of
CIMP-associated methylation (CIMP low) [25] which
may also demonstrate distinct features, including a
strong association with KRAS gene mutation [26].
CIMP classifications and methods for determining
methylation status in colorectal cancer
The classification of CIMP status has been under regular
development since first reported by Toyota et al. [27].
This group used combined bisulphite restriction analysis(COBRA) to quantify DNA methylation in a set of
33 cancer-specific genes and found 7 of these were
differentially methylated in a subset of cancers termed
CIMP positive.
Alternative methods for methylation analysis utilise
bisulphite conversion of DNA with subsequent direct
Sanger sequencing or more accurate methods of quan-
tification, such as pyrosequencing [28]. Methylation-
specific PCR (MSP) is a further technique utilising bisul-
phite conversion although it avoids the use of restriction
enzymes or sequencing and instead uses PCR primers
that are designed to be specifically complementary to ei-
ther methylated or unmethylated bisulphite-converted
DNA at CpG sites of interest. The so-called classical
panel of methylation markers, consisting of CDKN2A
(p16), MINT1, MINT2, MINT31 and MLH1, was devel-
oped by Park et al. [29] using MSP, and methylation of
two or more markers in this panel was deemed CIMP
high (CIMP H). Limitations of MSP include false posi-
tive results caused by incomplete bisulphite conversion
and denaturation of DNA caused by the bisulphite itself.
Furthermore, it only provides a qualitative result, and al-
though still popular due to its relative low cost and high
throughput, other more quantitative techniques such as
high-resolution mass spectrometry may provide a more
accurate characterisation of methylation status [30].
The MethyLight assay developed by Eads et al. [31]
utilises a refinement of MSP and has been used to
quantitatively assess methylation and is designed for
high throughput, small amounts of DNA and analysis
of multiple gene loci without the need for gel electro-
phoresis. DNA is bisulphate converted, amplified by
reverse transcriptase quantitative PCR using primers
containing an oligonucleotide probe with fluorescent
dye reporter. The intensity of fluorescence is propor-
tional to methylation quantity.
MethyLight analysis was used by Weisenberger et al.
[16] to further strengthen the evidence for a subset of
CIMP colorectal cancers. This group used MethyLight
analysis and hierarchical clustering to confirm a CIMP-
positive subset of cancers which was strongly related to
mutation of the BRAF gene [16]. This analysis used five
methylation-associated gene promoters, the so-called al-
ternative panel including CACNA1G, IGF2, NEUROG1,
RUNX3 and SOCS1, and classified tumours as CIMP
positive if four or more than five of this panel of pro-
moters were methylated.
Further investigation with this technique by Ogino et al.
[32] who examined methylation in 840 colorectal cancers
led to the proposal that a further subset of methylation-
associated tumours exists but which does not fulfil the
criteria for CIMP high. These tumours (termed CIMP low
if 1–3/5 promoters were methylated) were independently
associated with male gender and KRAS mutation. The
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et al. [25], who used a large-scale mass spectrometry ana-
lysis and hierarchical clustering to identify two panels of
markers, the first to identify CIMP-high tumours and then
a second panel to distinguish between CIMP-intermediate
and CIMP-low tumours. This group has also extended the
CIMP-intermediate KRAS association to colorectal aden-
omas [33]. There is as yet no consensus on the definitive
panel for classifying CIMP status; indeed, a recent study
by Berg [34] comparing several CIMP panels found sig-
nificant variability between published panels, with a two-
fold difference in CIMP positivity determined by the most
and least stringent panels.
In contrast to examining methylation at a small number
of loci, more recently, investigators have adopted a
genome-wide approach to the analysis of DNA methyla-
tion, extending the investigation to beyond the CIMP clas-
sification. Beggs et al. [35] used a methylation analysis
based on bisulphite conversion and whole-genome ampli-
fication and found that in ten colorectal cancer and five
colorectal adenoma specimens, quantification of whole-
genome methylation did not correlate with previously
published CIMP criterion. They also noted increasing
levels of methylation from progression of normal tissue
through adenoma and cancer cells.
Differential methylation across various individual and
groups of genes has therefore demonstrated distinct
associations with various clinicopathological features of
colorectal cancer. It is therefore possible that these asso-
ciations may extend to differential response rates to neo-
adjuvant treatment in rectal cancers, and the current
state of the art is discussed below.
Cell line studies
A small number of studies have modelled the effect of
radiotherapy upon colorectal cancer cells and the role of
differential methylation in determining the response of
these cells.
Kim et al. [36] investigated the role of methylation of the
ataxia telangiectasia mutated (ATM) gene in response to
10 Gy of ionising radiation (IR) in mismatch-repair-
deficient cell lines from patients with hereditary non-
polyposis colorectal cancer. They found a significantly
greater response to IR in cells with a hypermethylated ATM
gene promoter that was found to be associated with re-
duced ATM expression, and this was reversed by treatment
of cell lines with 5-azacytidine (5-AZA) a demethylating
agent. Similar results have been demonstrated in glioma
cells, whereby ATM promoter methylation was associated
with twofold enhancement of radiosensitivity [37]. The
ATM gene product is a protein kinase, activated by DNA
damage, and initiates cell cycle arrest whereby either DNA
damage repair or apoptosis occurs. Loss of this functioning
gene is demonstrated in patients with ataxia telangiectasiawho display 70 times higher risk of leukaemia and 250
times higher risk of lymphoma than normal individuals
[38]. The hypermethylation-associated loss of ATM func-
tion thereby leads to gross genetic instability which may ex-
plain the enhanced radiosensitivity in these cells and should
therefore be further investigated in studies of patients with
rectal cancer.
In contrast, Hofstetter [39] reported that treatment of
four CRC cell lines with AZA caused demethylation of
CDKN2A (p16) and hMLH-1 genes and resulted in en-
hanced radiation sensitivity of these cell lines treated
with up to 10 Gy. The p16 protein is a cyclin-dependent
kinase inhibitor which regulates cell cycle progression,
and hMLH-1 is a DNA mismatch repair gene. Although
a mechanism explaining this enhanced sensitivity with
demethylation has not been elucidated experimentally,
the role of these genes is closely linked at the G1/S tran-
sition phase of the cell cycle, and the subsequent fate of
irradiated cells containing DNA damage at this point of
the cell cycle would be influenced by alterations in ex-
pression of these two genes. In particular, one study
which found enhanced radiosensitivity of CDKN2A mu-
tant head and neck cancer cell lines found an extended
G2 arrest phase and increased frequency of double-
stranded DNA breaks in these cells and concluded that
compromised DNA repair was responsible for this
enhancement of the response to radiotherapy [40].
These studies suggest that the role of methylation in
response to radiation may be specific to several factors
including genotype and target tissue, and although the
effect of methylation status on radiosensitivity is as yet not
clearly defined in colorectal cancer cell lines, studies in
non-colorectal tissues have suggested that, overall, the
least methylated tissues are more radiosensitive [41] and
that the de novo DNA methyltransferases are important
targets for future investigation for mechanistic explana-
tions of radiosensitivity [42]. In clinical practice, a combin-
ation of radiotherapy with chemotherapeutic agents is
used. The chemotherapeutic agent 5-fluorouracil in com-
bination with radiotherapy is the most well-established
neoadjuvant regime [43] and has been demonstrated to
increase the sensitivity of cells to radiotherapy, thereby
improving the local effectiveness of radiotherapy in vitro
and in patient studies [44]. The relative combination of
chemotherapy, radiotherapy and methylation status to
outcome has not been well investigated at the cellular
level, presumably due to the technical difficulties in creat-
ing a representative cell line model.
Tumour regression in response to neoadjuvant treatment
and relationship to methylation
There has also been relatively little in vivo or ex vivo
study of the role of methylation in determining progno-
sis or response of rectal cancer to treatment.
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with specific regard to its effect upon tumour regression
or response to neoadjuvant chemoradiotherapy. Ebert
et al. [45] reported a significant relationship between
hypermethylation of the transcription factor activating
protein 2 epsilon (TFAP2E) gene and response to neoad-
juvant chemoradiotherapy. They found that patients
with either primary rectal cancer or metastatic colorectal
cancer with TFAP2E gene hypermethylation showed sub-
sequent reduction in TFAP2E protein expression and
poor response to treatment as assessed both histologi-
cally and by radiological criteria. With specific regard to
the response of rectal cancer patients, only 10 % of pa-
tients with hypermethylated TFAP2E showed a tumour
regression response in comparison to 82 % of those with
hypomethylated TFAP2E. These differences were seen in
patients treated with neoadjuvant radiotherapy and the
chemotherapeutic agent 5-fluorouracil (5-FU), either
alone or in combination with irinotecan and cetuximab.
The authors suggested TFAP2E downregulates DKK4,
itself an antagonist of the wingless/integration (WNT)
signalling pathway. This pathway has also been impli-
cated in hypermethylation-mediated effects on the re-
sponse of other cancers including head and neck and
ovarian [11] although the precise mechanisms mediating
radioresistance are still unknown. Recently, Beggs et al.
have identified TFAP2E hypermethylation to actually
confer a survival advantage in colorectal cancer subsets
and have suggested differential methylation of TFAP2E
may be more complex than previously understood. They
identified differential hyper- and hypomethylation across
various CpG sites within the TFAP2E promoter region
and noted, unlike Ebert, a significant relationship be-
tween this and BRAF mutation, suggesting that the
MAPK pathway may also mediate the relationship
between TFAP2E methylation and outcomes [46].
In the same year, Jo et al. [23] examined the CIMP status
(classifying into either positive or negative) in over 100 pa-
tients with rectal cancer undergoing 5-FU-based neoadju-
vant chemoradiotherapy. Post-chemoradiotherapy tumour
regression in the resected specimen was compared with the
pretreatment biopsy CIMP status; however, no significant
relationship between these variables was found. Also, in
contrast to other investigators, no association was reported
between CIMP status and KRAS or BRAF mutation.
In contrast to the above group, recently, Sun et al.
[47] examined the response to 5-FU-based chemora-
diotherapy in 219 rectal cancer patients and found
improved response to treatment in those patients
with hypermethylated MGMT promoters at baseline.
In this study, 88.9 % of patients with good response
and higher regression scores demonstrated hyperme-
thylation of MGMT, compared to 50 % of those in
the poor response group (P = 0.04).Although a precise mechanism has not been identified
in the literature, MGMT is a DNA repair enzyme and it
is therefore logical that hypermethylation and subse-
quent inactivation of this enzyme could lead to an en-
hanced effectiveness of ionising radiation by reducing
the cells’ capacity to repair the nuclear damage inflicted
by the therapy, thereby driving the cell into apoptosis.
Similarly, Molinari et al. [48] found hypermethylation
of the TIMP3 tumour suppressor gene appeared to be
associated with improved response to 5-FU-based neo-
adjuvant chemoradiotherapy. They found that tumours
demonstrating no response to CRT harboured signifi-
cantly lower rates of TIMP3 methylation compared to
those demonstrating some response (1–2 methylation
frequency 1–2 % vs 2–3 %, P = 0.015) although the asso-
ciation did not reach statistical significance for compari-
son of complete responders vs non-responders, and
there was wide variation in the data. Furthermore, exam-
ination of 23 other tumour suppressor genes in the same
analysis yielded no differences in methylation and re-
sponse; therefore, the authors urged caution that TIMP3
is not likely to be a principle marker of radiosensitivity
in rectal cancer.
This science is still in its infancy, and as yet, there
have been no large-scale studies investigating multiple
panels of markers of methylation and their specific role
in radiosensitivity of rectal cancer. To date, the best
available evidence is from heterogenous studies investi-
gating individual or small groups of relatively unrelated
genes, and as such, it is difficult to draw wider ranging
conclusions. From the limited published studies, it is
clear that the relationship between response and methy-
lation can be contrasting and depends upon the target
gene studied, and although some promise has been dem-
onstrated in a few markers, larger prospective studies
are required before these could impact clinical practice.
Outcomes and survival in relation to methylation
There are conflicting reports in the literature regarding
the prognostic implication of CIMP status and DNA
methylation as a whole.
Several studies have implicated CIMP positivity as an
adverse survival predictor in patients with colorectal
cancer [28, 49, 50]; however, the majority of studies in-
vestigating survival outcomes in relation to methylation
status regard colon and rectal cancers as one entity.
A study of rectal cancer patients by Jo et al. [23], also
discussed in the previous section, also compared survival
after neoadjuvant chemoradiotherapy in over 100 rectal
cancer patients. The 3- and 5-year survivals were signifi-
cantly worse in the 10 % of patients who were CIMP
positive (56 and 0 % vs 80 and 75 %; P < 0.01).
These findings, however, were not corroborated by
Kohonen-Corish et al. [51] who, amongst other molecular
Williamson et al. Clinical Epigenetics  (2015) 7:70 Page 5 of 9features, examined CIMP status and CDKN2A gene methy-
lation in nearly 400 rectal cancers. They found CIMP-H
status was a rare phenomenon (4 %), but was not itself
associated with adverse outcomes including survival.
CDKN2A methylation itself was again not associated
with poor survival; however, the joint presence of
CDKN2A methylation and KRAS mutation was inde-
pendently associated with poor survival and increased
risk of local recurrence. In this study, 95 % of patients
had not received neoadjuvant chemoradiotherapy thereby
making it difficult to determine the relative contribution
of this treatment when making comparisons with other
studies.
CDKN2A/p16 methylation has been the subject of sev-
eral studies, and two recent meta-analyses including
over 3000 patients with colorectal cancer have revealed
a strong association of CDKN2A/p16 methylation with
adverse survival, lymph node metastasis and lymphovas-
cular invasion [52, 53].
Bae et al. [54] reported worse survival in CIMP-H colo-
rectal cancer patients; however, after multivariate analysis,
only CIMP-H rectal cancers (n = 168) remained signifi-
cantly associated with poor survival (HR 4.13, P = 0.019)
in contrast to other colorectal subsites which were not
significant. Patients undergoing neoadjuvant chemora-
diotherapy were excluded in this study.
Conversely, genomic hypomethylation has been re-
ported as a poor prognostic feature in several studies.
Benard et al. [55] performed a similar analysis for
nearly 100 patients with early rectal cancer and found
that hypomethylation of the long interspersed nuclear
element type 1, L1 (LINE-1) non-coding DNA repeat se-
quence was associated with worse survival (hazard ratio
4.56, P = 0.014) and higher risk of tumour recurrence
(hazard ratio 9.57, P = 0.001). As LINE-1 repeat se-
quences form approximately 17 % of the human gen-
ome, these were considered to be a marker of global
methylation in this study. Similarly, these patients had
not undergone neoadjuvant radiotherapy, making it diffi-
cult to determine the role of this marker in the effect of
response to neoadjuvant treatment. LINE-1 sequences
are capable of their own expansion and mobilisation and
contribute to genetic recombination events that can dra-
matically alter the shape of the genome. LINE-1 activa-
tion may result in genetic deletions and double-stranded
DNA breaks which contribute to genetic instability.
Studies in rats [56] have demonstrated ionising radiation
caused a reduction in LINE-1 promoter methylation,
increasing its activity, which may contribute to genetic
instability and provide a mechanism for the phenomena
observed by Benard.
Recently, Gaedcke et al. [57] applied a whole-genome
methylation analysis to identify several differentially
methylated regions (DMR), in which high-pretreatmentlevels of methylation imparted a better prognosis in
terms of disease-free survival in 165 patients in three co-
horts treated for locally advanced rectal cancer (hazard
ratios between 3.57 and 4.09, P < 0.05). These cohorts
included a tight group of selected patients undergoing
standardised 5-FU-based chemoradiotherapy as well as a
more heterogenous group undergoing radiotherapy as
monotherapy or in combination at various doses with
various agents including oxaliplatin. However, this study
did not a report specific analysis of tumour regression.
Interestingly, the authors applied a similar analysis to
previously reported CIMP markers (which did not fea-
ture in the main DMR study group) and found some
minor differences in disease-free survival between CIMP
groups, with the hypermethylated phenotype imparting a
better survival, although this did not reach significance
and did not improve the prognostic utility when com-
bined with the DMR panel proposed by this study.
Simultaneous hyper- and hypomethylation within pa-
tients has also been demonstrated to have some prognos-
tic utility. De Maat et al. [58] investigated methylation at
several methylated in tumour (MINT) loci. These MINT
loci are non-protein-encoding CpG-rich regions which
have been previously identified as hypermethylated in
colorectal cancer and form part of many CIMP marker
panels. This group identified a cohort of rectal cancer pa-
tients undergoing surgery without neoadjuvant treatment
in whom hypermethylation at MINT3 and hypomethyla-
tion at MINT17 loci were associated with a significantly
reduced risk of local recurrence compared with others not
demonstrating these epigenetic features. This group
(which may account for up to 30 % of all rectal cancers)
was also compared to patients undergoing neoadjuvant
chemoradiotherapy and surgery and was found to have
similar local recurrence rates after 8 years of follow-up,
indicating that this group may be spared the risks of neo-
adjuvant chemoradiotherapy with no significant increase
in recurrence rates. The MINT loci have no protein-
encoding function of their own; however, they lie near
coding regions for genes including RBBP4, YARS and
HRK which are involved in histone deacetylation, angio-
genesis and apoptotic regulation, respectively. No func-
tional or regulatory relationship has been identified
between MINT3 and MINT17, and so, the authors con-
clude their role is of a surrogate biomarker at present.
It is likely that the heterogeneous nature of colorectal
cancer patients, CIMP marker panels, tumour location
along colorectal subsites and the highly complex nature
of the multitude of molecular pathways and their inter-
actions is only just being realised, and more work will be
required to clearly elucidate these complex interactions.
Indeed, there is emerging evidence that given their sep-
arate embryological origins, the rectum should be con-
sidered as a separate organ to the colon [59] and that
Table 1 Summary of methylation markers
Author Marker Study population Response to treatment Treatment given Other findings
Kim 2002 [36] ATM methylation Human HNPCC-
deficient CRC cell lines
Hypermethylation associated with
increased response to IR
10 Gy radiation Reversal of gene suppression and increased response
after AZA treatment
Hofstetter 2010 [39] P16 and hMLH-1
methylation
Human CRC cell lines
(×4)
Demethylation of markers resulted in
enhanced radiation sensitivity
10 Gy radiation N/A





Hypomethylation of bone marrow
associated with increased radiation
sensitivity
3 Gy radiation N/A
Ebert 2012 [45] TFAP2E methylation 110 human locally
advanced rectal cancers
Hypermethylation associated with
markedly reduced response to




Possible mechanism via WNT signalling pathway
Jo 2012 [23] CIMP status +/− 150 human locally
advanced rectal cancers
No association of pathological
response to IR with CIMP status
Treatment dose radiotherapy and
5-FU chemotherapy
Increased risk of distant metastases and poorer
5-year survival with CIMP +
Sun 2014 [47] MGMT methylation 219 rectal cancer
patients
MGMT hypermethylation associated




Molinari 2013 [48] TIMP3 methylation 74 rectal cancer
patients
TIMP3 hypomethylation associated
with poor tumour regression
Treatment dose radiotherapy
and 5-FU chemotherapy
Several genes including APC found differentially





381 early rectal cancers Not examined Primary surgery for majority
of patients
CIMP H or CDKN2A not independently associated
with survival. CDKN2A and KRAS mutation associated
with poor survival and increased recurrence
Bae 2013 [54] CIMP status H/L/0 168 rectal cancers
(stages I–IV)
Not examined Primary surgery only CIMP H associated with poor survival
Benard 2013 [55] LINE-1 methylation 94 early rectal cancers Not examined Primary surgery only Hypomethylation of LINE-1 associated with increased
risk of recurrence and poor survival




Not examined 3 cohorts including neoadjuvant
5-FU, oxaliplatin and radiotherapy
10 differentially methylated regions (DMRs),
hypermethylation of which predicts improved
disease-free
survival
De Maat 2010 [58] MINT loci 251 rectal cancer
patients (stages I–III)
Not examined Primary surgery only MINT 3 hyper- and MINT 17 hypomethylation
predicts reduced risk of recurrence similar to
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status along the length of the lower GI tract [24].
Heterogeneity of DNA and epigenetic phenomena has
also been implicated within tumours and subsequent
sampled cell types [60] and across patient age groups
[61]. It is likely that variability between these features
as well as gender and race may also account for dif-
ferences observed in the prognostic utility of methyla-
tion markers across various studies.
Most investigators identify CIMP as an adverse
prognostic feature, particularly in colorectal cancer
taken as a whole, and this was also corroborated by
a recent meta-analysis including all colorectal sub-
sites, which found shorter survival in CIMP-positive
patients [62]. The authors of this analysis stated that
the limitations of their analysis are due to the lack
of a standardised characterisation of CIMP status.
Furthermore, no mechanism for the role of CIMP in
adverse prognosis of colorectal cancer has yet been
proposed and satisfactorily demonstrated in the lit-
erature. See Table 1 for summary of methylation
markers discussed.
Conclusions
The use of appropriate neoadjuvant treatment and surgical
approach relies on accurate pretreatment risk stratification,
particularly with regard to local invasion and circumferen-
tial margin involvement. The current gold standard staging
tool is magnetic resonance imaging (MRI) which can be
used to accurately predict those with ‘good prognosis’
tumours which may be managed with surgery alone result-
ing in local recurrence rates of just 3 % [63].
With these advances in risk stratification and surgical
technique, there have been calls for a move away from the
use of neoadjuvant chemoradiotherapy in selected cases
[64]. The contribution of an effective and reliable bio-
marker to this risk stratification process is an exciting pro-
spect, and there is evidence that methylation markers may
have an important role. This may be used to identify likely
non-responders in selected groups such as in borderline
cases where there may be only marginal benefits of neoad-
juvant treatment or those in which it is difficult to balance
benefit against the risk of adverse effects, including disease
progression where a delay in surgery could be detrimental.
Currently, there are no means to predict response to treat-
ment; however, methylation markers could be validated to
identify those unlikely to respond to permit primary sur-
gery. Conversely, if methylation markers are able to identify
those likely to exhibit a pathological complete response, it
is conceivable that patients could potentially be treated with
neoadjuvant chemoradiotherapy.
Currently, the methods for determining methylation,
classification into prognostic groups such as CIMP and
their utility in predicting response to therapy remain underinvestigation. However, to date, the evidence suggests that
both hyper- and hypomethylation may predict outcomes
and response to treatment and that demethylation of
tissues may improve response to ionising radiation. Fur-
thermore, this evidence has been gathered from in vitro,
ex vivo and in vivo studies. The role of combination bio-
markers has not been well established, and this may require
further clarification of the role of methylation in specific
sites as well as collaborative research with other well-
established predictive markers such as KRAS mutation
which has already been associated with CIMP status. Our
understanding of this area may be improved by refinement
of the markers of the CIMP panel as well as identification
of other prognostic associations of the CIMP phenotype.
Furthermore, it is recommended that future studies report
the behaviour of rectal and colonic cancers separately as it
is evident that these are distinct entities, both in terms of
response to treatment and molecular characteristics. Sev-
eral potential methylation markers with clinical application
have been identified in the literature; however, the mecha-
nisms for their role are not yet well understood. In particu-
lar, the precise interactions between hyper- and
hypomethylation of candidate markers are not clear, and it
is proposed that further study in this regard is desirable.
Furthermore, given the evidence for the predictive role of
several key markers in determining response and out-
comes, in particular TFAP2E, MINT and DMRs, further
prospective trials of their use should be considered.
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